San Diego-dependent Viking Therapeutics marked by itself as a significant competitor from the weight loss drug industry in February just after revealing promising details from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March the co